A soft tissue sarcoma (STS) is a malignant tumor that starts in soft tissue such as muscle, deep skin tissues, cartilage, or fat. It often occurs as a lump in the arm, although it can happen anywhere.

The exact cause of soft tissue sarcoma is often unknown, but several risk factors have been identified. These include genetic predispositions, such as mutations in certain genes (e.g., TP53 ...

The following is a summary of "Impact of CT-based adipose tissue distribution and sarcopenia on treatment outcomes in ...

A phase 2 study showed that giving maintenance regorafenib could delay disease progression in patients with non-adipocytic ...

Introduction The global Soft Tissue Sarcoma (STS) market has demonstrated significant growth potential, with projections estimating the market to grow at a Compound Annual Growth Rate (CAGR) of 7.4% ...

An artificial intelligence (AI)-based model accurately classified pediatric sarcomas using digital pathology images alone, ...

Not much is known about this difficult disease sarcoma cancer because it is easy to ignore the small lumps in the beginning ...

According to the National Cancer Institute, undifferentiated pleomorphic sarcoma typically forms in the soft tissue (though it can also form in bone) and usually occurs in the legs, arms ...

The FDA has given accelerated approval to a groundbreaking T cell-based therapy from Adaptimmune for synovial sarcoma, becoming the first new treatment for the rare soft tissue cancer in more than ...

The 7MM soft tissue sarcoma (STS) market is estimated to reach USD 6,465.7 million by 2030 from USD 2,943.3 million in 2019 at a CAGR of 7.4%.